Kevin Robertson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kevin Robertson has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bibilola Damilola Oladeji
College of Medicine, university of Ibadan
2 shared publications - Sarah Yosief
University of North Carolina School of Medicine
2 shared publications Alyssa C Vecchio
Department of Neurology, University of North Carolina, Chapel Hill, NC 27599-7025, USA
1 shared publicationBibilola D. Oladeji
1 shared publication- Christopher Power
University of Alberta
1 shared publication - Chrysoula Zografou
Department of Neurology
1 shared publication
Latest Publications
- 1 July 2019
- Published by Elsevier in The Lancet HIV
- Vol. 6 (7) , e416-e417
Markers of persistent HIV replication in the CNS
- 1 July 2019
- Published by Elsevier in The Lancet HIV
- Vol. 6 (7) , e416-e417
Markers of persistent HIV replication in the CNS
- Open Access
- 20 September 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (18)
Single-cell RNA sequencing reveals microglia-like cells in cerebrospinal fluid during virologically suppressed HIV
Central nervous system (CNS) immune activation is an important driver of neuronal injury during several neurodegenerative and neuroinflammatory diseases. During HIV infection, CNS immune activation is associated with high rates of neurocognitive impairment, even during sustained long-term suppressive antiretroviral therapy (ART). However, the cellular subsets that drive immune activation and neuronal damage in the CNS during HIV infection and other neurological conditions remain unknown, in part because CNS cells are difficult to access in living humans. Using single-cell RNA sequencing (scRNA-seq) on cerebrospinal fluid (CSF) and blood from adults with and without HIV, we identified a rare (<5% of cells) subset of myeloid cells that are found only in CSF and that present a gene expression signature that overlaps significantly with neurodegenerative disease–associated microglia. This highlights the power of scRNA-seq of CSF to identify rare CNS immune cell subsets that may perpetuate neuronal injury during HIV infection and other conditions.
- 20 September 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (18)
Open AccessSingle-cell RNA sequencing reveals microglia-like cells in cerebrospinal fluid during virologically suppressed HIV
Central nervous system (CNS) immune activation is an important driver of neuronal injury during several neurodegenerative and neuroinflammatory diseases. During HIV infection, CNS immune activation is associated with high rates of neurocognitive impairment, even during sustained long-term suppressive antiretroviral therapy (ART). However, the cellular subsets that drive immune activation and neuronal damage in the CNS during HIV infection and other neurological conditions remain unknown, in part because CNS cells are difficult to access in living humans. Using single-cell RNA sequencing (scRNA-seq) on cerebrospinal fluid (CSF) and blood from adults with and without HIV, we identified a rare (<5% of cells) subset of myeloid cells that are found only in CSF and that present a gene expression signature that overlaps significantly with neurodegenerative disease–associated microglia. This highlights the power of scRNA-seq of CSF to identify rare CNS immune cell subsets that may perpetuate neuronal injury during HIV infection and other conditions.
- 1 June 2017
- Published by Oxford University Press (OUP)
Neuropsychological Evaluation for Persons with HIV and AIDS
With recent developments in the classification and definitions for HIV-associated neurocognitive disorders (HAND), neuropsychological assessments have become central to the diagnostic process. The pattern and manifestation of neurocognitive dysfunction associated with HIV have changed since the introduction of effective antiretroviral medications and their increasingly widespread use. Prior to the introduction of antiretroviral therapy, severe cognitive disorder presenting as HIV-associated dementia (HAD) was a common manifestation of HIV-associated neurocognitive disorders. In more recent times, however, milder forms of neurocognitive impairment have become more common, often being asymptomatic and difficult to recognize without formal neuropsychological testing. Hence, recognizing individuals at most risk for cognitive decline through neuropsychological testing will offer opportunities for developing targeted interventions that could delay disease progression and improve individual functioning and quality of life.
- 1 June 2017
- Published by Oxford University Press (OUP)
Neuropsychological Evaluation for Persons with HIV and AIDS
With recent developments in the classification and definitions for HIV-associated neurocognitive disorders (HAND), neuropsychological assessments have become central to the diagnostic process. The pattern and manifestation of neurocognitive dysfunction associated with HIV have changed since the introduction of effective antiretroviral medications and their increasingly widespread use. Prior to the introduction of antiretroviral therapy, severe cognitive disorder presenting as HIV-associated dementia (HAD) was a common manifestation of HIV-associated neurocognitive disorders. In more recent times, however, milder forms of neurocognitive impairment have become more common, often being asymptomatic and difficult to recognize without formal neuropsychological testing. Hence, recognizing individuals at most risk for cognitive decline through neuropsychological testing will offer opportunities for developing targeted interventions that could delay disease progression and improve individual functioning and quality of life.
- 31 October 2015
- Published by Springer Nature
- p. 1-9
Global NeuroAIDS
- 19 January 2015
- Published by Springer Nature
- p. 1-10
Global NeuroAIDS
- 30 September 2014
- Published by Springer Nature
- p. 1-7
Neurotoxic Consequences of Antiretroviral Therapies
- 30 September 2014
- Published by Springer Nature
- p. 1-7
Neurotoxic Consequences of Antiretroviral Therapies